---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034551"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:35:06.037469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q3 2024 revenue jumps to $1.96M; net loss narrows to $0.20M

## Summary
- Revenue of ~$1.958M vs $397K in Q3 2023, driven by $1M Proliant milestone and $425K Inzyme success fee.
- Net loss of $203K vs $1.614M a year ago; operating loss fell to $203K from $1.720M.
- Cash & investment-grade securities at $10.0M as of Sep 30, 2024, up from $7.3M at Dec 31, 2023.
- Received $1M milestone from Proliant for animal-free recombinant albumin; first product launch expected H1 2025.
- Advanced C1-produced Mpox antigen with ViroVax (4.5 g/L in 7 days); preclinical studies start Q4 2024.

## SEC filing metadata
- accession: 0001437749-24-034551
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/0001437749-24-034551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774924034551/dyai20240905_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034551
- JSON: https://secwatch.observer/filing/0001437749-24-034551.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.